サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1409685

小児神経芽腫治療の世界市場レポート 2024年

Pediatric Neuroblastoma Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
小児神経芽腫治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

小児神経芽腫治療の市場規模は近年急速に拡大しています。2023年の16億7,000万米ドルから2024年には18億4,000万米ドルへと、CAGR10.0％で拡大します。過去の期間に観察された成長は、治療方法の進歩、早期診断につながる認知度の向上、進行中の研究開発イニシアティブ、医療専門家や組織間の協力的な取り組み、小児神経芽腫の管理における生存率の向上など、いくつかの要因に起因しています。

小児神経芽腫治療市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR8.8％で25億8,000万米ドルに成長します。予測期間中に予想される成長は、新しい治療法の出現、個別化医療アプローチの導入、世界ヘルスイニシアチブ、治療へのアクセス向上、患者擁護・支援の積極的関与などの要因によるものと考えられます。予測期間中に予想される注目すべき動向としては、共同研究イニシアティブ、遺伝子治療におけるブレークスルー、新規薬剤治療法の研究開発、早期診断とスクリーニングの重視、患者擁護と支援の継続的重視などが挙げられます。

小児神経芽細胞腫の新規症例数の増加が予想され、小児神経芽腫治療市場の成長を牽引する構えです。神経芽腫の有病率の上昇は、小児患者に対する代替治療への需要を煽っています。その結果、製薬企業やその他の利害関係者は研究開発への投資を強化し、業界のイノベーションを促進しています。さらに、新しい診断技術やスクリーニング方法の出現により、神経芽腫の早期発見が容易になり、迅速な治療と転帰の改善が可能になった。例えば、米国臨床腫瘍学会（ASCO）が2023年3月に発表した論文によると、神経芽腫は米国で毎年約700～800人の幼児が罹患しており、小児悪性腫瘍全体の6％を占めています。さらに、神経芽細胞腫は5歳未満の小児の約90％に影響を与えています。したがって、小児神経芽細胞腫の新規症例の発生率の増加は、小児神経芽腫治療市場の重要な促進要因です。

ヘルスケアインフラの継続的な改善は、小児神経芽腫治療市場の成長に貢献すると期待されています。ヘルスケアインフラは、組織的・物理的構造、プロセス、リソースを包含し、小児神経芽腫患者の診断、治療、サポートの基盤として機能します。ヘルスケアインフラの様々な構成要素は、包括的な治療を提供し、研究とイノベーションを刺激し、神経芽腫の小児の全体的な健康を強化するために連携しています。例えば、2022年3月、オーストラリアのヘルスケア・高齢者医療省は、医療インフラのために2022-23年に過去最高の1,320億米ドルを投資すると発表し、2025-26年には1,400億米ドルに増額し、今後4年間で合計5,370億米ドルを投資する計画です。したがって、医療インフラの継続的強化が小児神経芽腫治療市場を推進しています。

2023年の小児神経芽腫治療市場で最大の地域は北米でした。小児神経芽腫治療市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 小児神経芽腫治療市場の特徴

第3章 小児神経芽腫治療市場の動向と戦略

第4章 小児神経芽腫治療市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の小児神経芽腫治療市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 小児神経芽腫治療市場セグメンテーション

  • 世界の小児神経芽腫治療市場、治療タイプ別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 免疫療法
  • 化学療法
  • 放射線治療
  • その他の治療タイプ
  • 世界の小児神経芽腫治療市場、リスクグループ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 低リスク
  • 中リスク
  • 高リスク
  • 世界の小児神経芽腫治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • その他のエンドユーザー

第7章 小児神経芽腫治療市場の地域および国分析

  • 世界の小児神経芽腫治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の小児神経芽腫治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋の小児神経芽腫治療市場

第9章 中国小児神経芽腫治療市場

第10章 インドの小児神経芽腫治療市場

第11章 日本の小児神経芽腫治療市場

第12章 オーストラリアの小児神経芽腫治療市場

第13章 インドネシアの小児神経芽腫治療市場

第14章 韓国の小児神経芽腫治療市場

第15章 西欧の小児神経芽腫治療市場

第16章 英国の小児神経芽腫治療市場

第17章 ドイツの小児神経芽腫治療市場

第18章 フランスの小児神経芽腫治療市場

第19章 イタリアの小児神経芽腫治療市場

第20章 スペインの小児神経芽腫治療市場

第21章 東欧の小児神経芽腫治療市場

第22章 ロシアの小児神経芽腫治療市場

第23章 北米小児神経芽腫治療市場

第24章 米国の小児神経芽腫治療市場

第25章 カナダの小児神経芽腫治療市場

第26章 南米小児神経芽腫治療市場

第27章 ブラジルの小児神経芽腫治療市場

第28章 中東の小児神経芽腫治療市場

第29章 アフリカの小児神経芽腫治療市場

第30章 小児神経芽腫治療市場の競合情勢と企業プロファイル

  • 小児神経芽腫治療市場の競合情勢
  • 小児神経芽腫治療市場の企業プロファイル
    • United Therapeutics Corporation
    • APEIRON Biologics AG
    • Baxter International Inc.
    • Cell Ectar Biosciences Inc.
    • Pfizer Inc.

第31章 世界の小児神経芽腫治療市場の競合ベンチマーキング

第32章 世界の小児神経芽腫治療市場競争力ダッシュボード

第33章 小児神経芽腫治療市場における主要な合併と買収

第34章 小児神経芽腫治療市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r11223

“Pediatric Neuroblastoma Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pediatric neuroblastoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pediatric neuroblastoma treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The pediatric neuroblastoma treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Treatment Type: Immunotherapy; Chemotherapy; Radiation Therapy; Other Treatment Types
  • 2) By Risk Group: Low Risk; Intermediate Risk; High Risk
  • 3) By End User: Hospitals; Specialty Clinics; Other End Users
  • Companies Mentioned: United Therapeutics Corporation; APEIRON Biologics AG; Baxter International Inc.; Cell Ectar Biosciences Inc.; Pfizer Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Pediatric neuroblastoma treatment refers to the medical interventions employed to address cancer or tumors affecting the nervous system in children. The treatment approach for neuroblastoma typically involves a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy.

The primary types of pediatric neuroblastoma treatments include immunotherapy, chemotherapy, radiation therapy, and other supplementary approaches. Immunotherapy is a medical treatment that harnesses the immune system's capabilities to combat diseases. It is applied across different risk groups, including low risk, intermediate risk, and high risk, and is utilized by various end users such as hospitals, specialty clinics, and other medical facilities.

The pediatric neuroblastoma treatment market research report is one of a series of new reports from The Business Research Company that provides pediatric neuroblastoma treatment market statistics, including pediatric neuroblastoma treatment industry global market size, regional shares, competitors with a pediatric neuroblastoma treatment market share, detailed pediatric neuroblastoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric neuroblastoma treatment industry. This pediatric neuroblastoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pediatric neuroblastoma treatment market size has grown rapidly in recent years. It will grow from $1.67 billion in 2023 to $1.84 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth observed in the historical period can be attributed to several factors, including advancements in treatment modalities, increased awareness leading to early diagnosis, ongoing research and development initiatives, collaborative efforts among healthcare professionals and organizations, and improved survival rates in the management of pediatric neuroblastoma.

The pediatric neuroblastoma treatment market size is expected to see strong growth in the next few years. It will grow to $2.58 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated growth in the forecast period can be attributed to factors such as the emergence of new therapies, the implementation of personalized medicine approaches, global health initiatives, increased access to treatment, and the active involvement of patient advocacy and support. Noteworthy trends expected in the forecast period include collaborative research initiatives, breakthroughs in gene therapy, developments in novel drug treatments, emphasis on early diagnosis and screening, and a continued focus on patient advocacy and support.

The anticipated increase in the number of new cases of pediatric neuroblastoma is poised to drive the growth of the pediatric neuroblastoma treatment market. The rising prevalence of neuroblastoma is fueling the demand for treatment alternatives for pediatric patients. Consequently, pharmaceutical corporations and other stakeholders are intensifying their investments in research and development, fostering innovation in the industry. Additionally, the advent of new diagnostic technology and screening procedures has facilitated the early detection of neuroblastoma, enabling prompt treatment and improved outcomes. For instance, a March 2023 article from the American Society of Clinical Oncology (ASCO) revealed that neuroblastoma affects approximately 700 to 800 youngsters in the United States each year, constituting 6% of all childhood malignancies. Moreover, neuroblastoma impacts around 90% of children under the age of five. Therefore, the increasing incidence of new cases of pediatric neuroblastoma is a significant driver of the pediatric neuroblastoma treatment market.

The ongoing improvement in healthcare infrastructure is expected to contribute to the growth of the pediatric neuroblastoma treatment market. Healthcare infrastructure, encompassing organizational and physical structures, processes, and resources, serves as the foundation for the diagnosis, treatment, and support of pediatric neuroblastoma patients. The various components of healthcare infrastructure collaborate to deliver comprehensive treatment, stimulate research and innovation, and enhance the overall health of children with neuroblastoma. For instance, in March 2022, the Department of Health and Aged Care in Australia announced a record investment of $132 billion in 2022-23 for healthcare infrastructure, with plans to increase it to $140 billion in 2025-26, totaling $537 billion over the next four years. Therefore, the ongoing enhancement of healthcare infrastructure is propelling the pediatric neuroblastoma treatment market.

Research and development emerge as a key trend gaining popularity in the pediatric neuroblastoma treatment market. Major companies in this sector are directing their efforts toward advanced research and development to maintain their positions. For instance, in March 2021, Ascentage Pharma Group Inc., a US-based pharmaceutical company specializing in novel cancer therapies, disclosed that the US Food and Drug Administration (FDA) had granted alrizomadlin (APG-115) a rare pediatric disease (RPD) designation for treating neuroblastoma. Alrizomadlin, an orally administered, selective, small-molecule antagonist of the MDM2 protein, aims to stimulate the tumor-suppressive activities of p53 by inhibiting the MDM2-p53 protein-protein interaction.

Major companies in the pediatric neuroblastoma treatment market are adopting a strategic partnership approach to develop novel drugs for high-risk neuroblastoma. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. For instance, in August 2023, Renaissance Pharma Ltd., a UK-based biopharmaceutical company, entered into a license agreement with St. Jude Children's Research Hospital for Hu14.18, a humanized antibody developed for managing newly identified high-risk neuroblastoma. Hu14.18, a humanized anti-GD2 monoclonal antibody, demonstrated promising outcomes in a Phase II study, and the licensing agreement grants Renaissance Pharma exclusive development, production, and commercialization rights in various regions, including the United States, Canada, Europe, China, Japan, and Turkey. St. Jude Children's Research Hospital is a renowned US-based research institution.

In March 2022, Recordati S.p.A., an Italy-based pharmaceutical group, acquired EUSA Pharma (UK) Ltd. for $824.28 million. The acquisition is expected to provide Recordati with an expanded portfolio of pharmaceuticals for rare diseases, including treatments for pediatric neuroblastoma. EUSA Pharma (UK) Ltd. is a UK-based specialty pharmaceutical company specializing in pediatric neuroblastoma treatment.

Major companies operating in the pediatric neuroblastoma treatment market report are United Therapeutics Corporation, APEIRON Biologics AG, Baxter International Inc., Cell Ectar Biosciences Inc., Pfizer Inc., MacroGenics Inc., Bayer AG, Provectus Biopharmaceuticals Inc., Sartorius AG, Y-mAbs Therapeutics Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Clarity Pharmaceuticals, CureSearch for Children's Cancer, Novartis AG, LEO Pharma A/S, UCB SA, Johnson & Johnson Services Inc., Abbott Laboratories, AbbVie Inc., Merck & Co. Inc., Sanofi SA, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd

North America was the largest region in the pediatric neuroblastoma treatment market in 2023. The regions covered in the pediatric neuroblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pediatric neuroblastoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pediatric neuroblastoma treatment market consists of revenues earned by entities by providing pediatric neuroblastoma treatment services such as stem cell therapy, supportive care and blood transfusions. The market value includes the value of related goods sold by the service provider or included within the service offering. The pediatric neuroblastoma treatment market also includes sales of pain management medications, chemotherapy drugs and immunotherapy agents which are used in providing pediatric neuroblastoma treatment services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Pediatric Neuroblastoma Treatment Market Characteristics

3. Pediatric Neuroblastoma Treatment Market Trends And Strategies

4. Pediatric Neuroblastoma Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Pediatric Neuroblastoma Treatment Market Size and Growth

  • 5.1. Global Pediatric Neuroblastoma Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Pediatric Neuroblastoma Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Pediatric Neuroblastoma Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pediatric Neuroblastoma Treatment Market Segmentation

  • 6.1. Global Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Immunotherapy
  • Chemotherapy
  • Radiation Therapy
  • Other Treatment Types
  • 6.2. Global Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Low Risk
  • Intermediate Risk
  • High Risk
  • 6.3. Global Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Other End Users

7. Pediatric Neuroblastoma Treatment Market Regional And Country Analysis

  • 7.1. Global Pediatric Neuroblastoma Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Pediatric Neuroblastoma Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pediatric Neuroblastoma Treatment Market

  • 8.1. Asia-Pacific Pediatric Neuroblastoma Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pediatric Neuroblastoma Treatment Market

  • 9.1. China Pediatric Neuroblastoma Treatment Market Overview
  • 9.2. China Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pediatric Neuroblastoma Treatment Market

  • 10.1. India Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pediatric Neuroblastoma Treatment Market

  • 11.1. Japan Pediatric Neuroblastoma Treatment Market Overview
  • 11.2. Japan Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pediatric Neuroblastoma Treatment Market

  • 12.1. Australia Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pediatric Neuroblastoma Treatment Market

  • 13.1. Indonesia Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pediatric Neuroblastoma Treatment Market

  • 14.1. South Korea Pediatric Neuroblastoma Treatment Market Overview
  • 14.2. South Korea Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pediatric Neuroblastoma Treatment Market

  • 15.1. Western Europe Pediatric Neuroblastoma Treatment Market Overview
  • 15.2. Western Europe Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pediatric Neuroblastoma Treatment Market

  • 16.1. UK Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pediatric Neuroblastoma Treatment Market

  • 17.1. Germany Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pediatric Neuroblastoma Treatment Market

  • 18.1. France Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pediatric Neuroblastoma Treatment Market

  • 19.1. Italy Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pediatric Neuroblastoma Treatment Market

  • 20.1. Spain Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pediatric Neuroblastoma Treatment Market

  • 21.1. Eastern Europe Pediatric Neuroblastoma Treatment Market Overview
  • 21.2. Eastern Europe Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pediatric Neuroblastoma Treatment Market

  • 22.1. Russia Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pediatric Neuroblastoma Treatment Market

  • 23.1. North America Pediatric Neuroblastoma Treatment Market Overview
  • 23.2. North America Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pediatric Neuroblastoma Treatment Market

  • 24.1. USA Pediatric Neuroblastoma Treatment Market Overview
  • 24.2. USA Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pediatric Neuroblastoma Treatment Market

  • 25.1. Canada Pediatric Neuroblastoma Treatment Market Overview
  • 25.2. Canada Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pediatric Neuroblastoma Treatment Market

  • 26.1. South America Pediatric Neuroblastoma Treatment Market Overview
  • 26.2. South America Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pediatric Neuroblastoma Treatment Market

  • 27.1. Brazil Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pediatric Neuroblastoma Treatment Market

  • 28.1. Middle East Pediatric Neuroblastoma Treatment Market Overview
  • 28.2. Middle East Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pediatric Neuroblastoma Treatment Market

  • 29.1. Africa Pediatric Neuroblastoma Treatment Market Overview
  • 29.2. Africa Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pediatric Neuroblastoma Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Pediatric Neuroblastoma Treatment Market Competitive Landscape
  • 30.2. Pediatric Neuroblastoma Treatment Market Company Profiles
    • 30.2.1. United Therapeutics Corporation
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. APEIRON Biologics AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Baxter International Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Cell Ectar Biosciences Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Pfizer Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Pediatric Neuroblastoma Treatment Market Competitive Benchmarking

32. Global Pediatric Neuroblastoma Treatment Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Pediatric Neuroblastoma Treatment Market

34. Pediatric Neuroblastoma Treatment Market Future Outlook and Potential Analysis

  • 34.1 Pediatric Neuroblastoma Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Pediatric Neuroblastoma Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Pediatric Neuroblastoma Treatment Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer